Abstract:518 Background: Despite high cure rate, small proportion of patients with germ cell tumors (GCTs) experience relapse and eventually die as a consequence of their disease. Tumor-derived DNA, but also total extracellular DNA (ecDNA) in plasma were found to be associated with the prognosis in different types of cancer. Deoxyribonuclease (DNase) catalyzes the cleavage of ecDNA and is likely the main metabolic pathway of ecDNA degradation. We hypothesized that DNase activity might modulate the association between ecDNA and prognosis. This study aimed to determine the prognostic value of ecDNA of different subcellular origin and plasma DNase activity in GCTs. Methods: This study included 117 patients with testicular GCTs starting a new line of therapy and 19 healthy controls. Plasma ecDNA was quantified using fluorometry (total ecDNA) and using PCR (nuclear – ncDNA and mitochondrial DNA – mtDNA). DNase activity was assessed using the single radial enzyme diffusion method in a DNA-containing gel. An in vivo experiment in mice was conducted to evaluate the effect of DNase I treatment alone and in combination with cisplatin on the xenografts derived from the human embryonal carcinoma cell line variant NTERA-2 CisR. Results: Plasma ecDNA was higher in patients with GCTs compared to healthy controls (mean ng/ml ± SEM: 6.2 ± 0.6 vs.1.2 ± 2.2). Patients with high total ecDNA, ncDNA but not mtDNA had inferior PFS and OS compared to patients with low ecDNA (all p < 0.05). There was an inverse relationship between plasma DNase and ecDNA as well as between plasma DNase and clinical outcome (HR=2.96, 95%CI 1.39-6.32, P = 0.01 for PFS and HR=4.88, 95%CI 2.06-11.53, p = 0.005 for OS, respectively). Our experiments on selected model human GCT cell lines confirmed the lack of cytotoxic or inhibitory effects of DNase I in vitro. The animal experiment showed that the combination treatment with DNase I and cisplatin substantially reduced the growth of the NTERA-2 cisplatin-resistant xenografts (by 30%). Conclusions: We confirmed the prognostic value of ecDNA and proved it for the first time for DNase in patients with GCTs. We suggest that based on the animal experiment there is strong rationale to add DNase to cisplatin in refractory GCTs. Although the mechanisms are unclear and could involve reduced inflammatory response to ecDNA, we hypothesize that degradation of ecDNA by DNase might contribute to a better control of the tumor progression by cisplatin in patients with progressing or relapsing GCTs.

Plasma DNA and deoxyribonuclease in testicular germ cell tumors.